(Q51381364)

English

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study.

scientific article published on 19 January 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

0 references

type 2 diabetes

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

G E Umpierrez

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

T Blevins

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

J Rosenstock

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

C Cheng

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

J H Anderson

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

E J Bastyr

6

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

EGO Study Group

7

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

publication date

19 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

13

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

418-425

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

The incretin system and its role in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Use and abuse of HOMA modeling

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01366.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2011.01366.X

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/21251180

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51381364&oldid=1203204330"